Inhibrx Shares Interim Data On INBRX-106 - Keytruda Combo Therapy In Solid Tumors


Inhibrx Inc INBX announced initial results from Part 3 (combination dose escalation) of the Phase 1 trial of INBRX-106 combined with Keytruda for solid tumors. 

  • The dose of INBRX-106 was escalated in combination with Keytruda in 21 patients with locally advanced or metastatic solid tumors. 
  • INBRX-106 combo regime was observed to be well tolerated, with predominantly mild or moderate immune-related toxicities noted. 
  • The maximum administered dose of INBRX-106 was 0.3 mg/kg, at which dose-limiting, immune-related toxicities such as dermatitis were observed. 
  • Accordingly, 0.1 mg/kg dosed every three weeks was determined to be the maximum tolerated dose (MTD) of INBRX-106 combined with Keytruda.
  • Out of five responses, evaluable patients with tumor types responsive to immunotherapy, two durable partial responses were achieved in checkpoint inhibitor naïve nasopharyngeal carcinoma and uveal melanoma patients with a duration greater than six months with treatment ongoing. 
  • Additionally, a third checkpoint inhibitor exposed cutaneous melanoma patient has a double-digit reduction in tumor volume and duration greater than four months with treatment ongoing.
  • Price Action: INBX shares closed at $39.46 on Tuesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareSmall CapGeneralBriefsPhase 1 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!